Radny Peter, Eigentler Thomas Kurt, Soennichsen Karsten, Overkamp Dietrich, Raab Hans-Rudolf, Viebahn Richard, Mueller-Horvart Christian, Sotlar Karl, Rassner Gernot
Department of Dermatology, University of Tuebingen, Tuebingen, Germany.
J Am Acad Dermatol. 2006 Feb;54(2):344-7. doi: 10.1016/j.jaad.2005.05.023.
Glucagonoma is a rare pancreatic endocrine tumor that is often both well developed and malignant at detection. In the case of metastatic spread the patient has a poor long-term prognosis. We hope to familiarize dermatologists and other specialists with this rare and potentially fatal disorder because early recognition of necrolytic migratory erythema, a clinical feature that may appear in patients with glucagonoma, can lead to possible cure, whereas delayed identification of the disease is associated with metastatic disease and a poor prognosis. We report the case of a 57-year-old patient with a metastatic glucagon-producing tumor; necrolytic migratory erythema was diagnosed and was successfully treated by a multimodal intervention including liver transplantation. Currently, 72 months after transplantation, our patient is in complete remission, which has been verified by somatostatin receptor scintigraphy monitoring, computed tomographic scanning and glucagon serum control. Increased awareness of the clinical symptoms and visible polymorphic mucocutaneous and nonspecific histopathologic features of glucagonoma syndrome is needed to avoid unnecessary delay in the diagnosis of this syndrome.
胰高血糖素瘤是一种罕见的胰腺内分泌肿瘤,在被发现时通常已发展成熟且具有恶性特征。发生转移扩散时,患者的长期预后较差。我们希望让皮肤科医生和其他专科医生熟悉这种罕见且可能致命的疾病,因为早期识别坏死性游走性红斑(一种可能出现在胰高血糖素瘤患者身上的临床特征)可能带来治愈的可能,而疾病的延迟诊断则与转移性疾病和不良预后相关。我们报告了一例57岁患有转移性产胰高血糖素肿瘤的患者;诊断出坏死性游走性红斑,并通过包括肝移植在内的多模式干预成功进行了治疗。目前,移植后72个月,我们的患者处于完全缓解状态,这已通过生长抑素受体闪烁扫描监测、计算机断层扫描和胰高血糖素血清检测得到证实。需要提高对胰高血糖素瘤综合征临床症状以及可见的多形性皮肤黏膜和非特异性组织病理学特征的认识,以避免对该综合征的诊断出现不必要的延误。